Clinical Trials Logo

Clinical Trial Summary

Understanding the impact exercise has on a cancer survivor's gut microbiome can improve the health and well-being of cancer survivors by enhancing treatments targeting the gut microbiome. Although scientific studies support a link between exercise and the gut microbiome, rigorous randomized trials needed to confirm this causal link are limited and usually involve supervised exercise. Hence, this proposal tests feasibility of a home-based, remote-only research protocol that is more accessible to cancer survivors unable to attend supervised exercise including but not limited to rural populations. This study will also determine if exercise effects on the gut microbiome differ by factors such as race.


Clinical Trial Description

Forty physically inactive breast cancer survivors will be randomized into 10-week conditions of home-based aerobic exercise training or standard attention control. All participants will be asked to maintain their pre-study diet and attempt to maintain their body weight while participating in the study. Assessments will occur at baseline, week 5 (mid-intervention), and week 10 (post-intervention) by videoconference platform. Study feasibility and changes in the gut microbiome will be assessed. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05000502
Study type Interventional
Source University of Alabama at Birmingham
Contact
Status Completed
Phase N/A
Start date September 1, 2021
Completion date January 31, 2024

See also
  Status Clinical Trial Phase
Active, not recruiting NCT02480933 - Silent Breast Cancer A Study of the Disease Prevalence Held by Imaging Guided Biopsies in Autopsy Specimens N/A
Not yet recruiting NCT04863833 - Tomosymthesis for Breast Mass Lesion Characterization
Recruiting NCT06145399 - A Study of 1 8F-FDHT PET/MRIScans in Women With Breast Cancer Early Phase 1
Suspended NCT01320488 - Breast Cancer in Young Women: Is it Different? N/A
Recruiting NCT02089854 - Adjuvant Endocrine Therapy for Estrogen Receptor-beta Positive Triple Negative Breast Cancer Phase 4
Active, not recruiting NCT01741883 - Side Effect Prevention Training (SEPT) for Nocebo Effects in Breast Cancer Patients N/A
Recruiting NCT06144164 - A Study of a Comprehensive Prevention Program to Reduce Lymphedema After Axillary Lymph Node Dissection in People With Breast Cancer Phase 3
Recruiting NCT06331793 - Pulsed Electromagnetic Fields for Analgesia Post Mastectomy N/A
Recruiting NCT05439499 - This is a Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study Evaluating the Efficacy and Safety of FCN-437c Versus Placebo in Combination With Letrozole or Anastrozole ± Goserelin in Women With HR+ and HER2- Advanced Breast Cancer. Phase 3
Terminated NCT03836872 - Acupuncture for Joint Symptoms in Patients With Breast Cancer N/A
Recruiting NCT06332976 - PrefeRences And ChemoTherapy In Breast Cancer patiEnts
Completed NCT01671319 - Dose Dense TC + Pegfilgrastim Support for Breast Cancer Phase 2
Not yet recruiting NCT06092892 - IIT2023-09-Chung-UpfrontTAD: Upfront TAD/SNB in Patients With Breast Cancer With Nodal Metastases Phase 2
Recruiting NCT05586256 - Ultra-hypofractionated Radiotherapy in Breast Cancer Patients
Not yet recruiting NCT03153631 - Female Sexual Dysfunction in Breast Cancer Patients N/A
Active, not recruiting NCT03059875 - Place of Comprehensive Geriatric Assessment in Patients ≥ 75 Years Care, With Breast Cancer, After Screening With FOG (Oncology Geriatric Filter) N/A
Active, not recruiting NCT02088710 - Expectations and Side Effects of Endocrine Therapy in Women With Breast Cancer N/A
Terminated NCT01083641 - Estrogen for Triple Negative Breast Cancer Phase 2
Recruiting NCT05374161 - An Intervention for Female Breast CANcer: Acceptance and Commitment Therapy (I-CAN-ACT) for Depression and Physical Pain N/A
Recruiting NCT05438810 - This is a Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study Evaluating the Efficacy and Safety of FCN-437c in Combination With Fluvestrant ± Goseraline Versus Placebo Combined With Fulvestrant ± Goserelin in Women With HR+ and HER2- Advanced Breast Cancer. Phase 3